5 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 8 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 1 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Forma Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke Etavopivat, Hydroxyurea - Sickle Cell Disease | Phase 2 | Recruiting | Forma Therapeutics, Inc. | 27 | 2023-06-20 | 2026-09-10 |
| A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease Etavopivat - Sickle Cell Disease | Phase 2 | Recruiting | Forma Therapeutics, Inc. | 95 | 2023-01-12 | 2026-09-18 |
| A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) Etavopivat - Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R | Phase 2 | Terminated | Forma Therapeutics, Inc. | 17 | 2022-11-15 | 2026-09-03 |
| A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease Etavopivat tablets - Sickle Cell Disease, Thalassemia | Phase 2 | Completed | Forma Therapeutics, Inc. | 53 | 2022-03-28 | 2025-12-16 |
| A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets - Sickle Cell Disease | Phase 3 | Active not recruiting | Forma Therapeutics, Inc. | 450 | 2021-01-29 | 2026-04-06 |
| ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, IDH-1 Inhibitor FT-2102 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2019-08-27 | 2020-07-07 | |
| A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis FT-4101, FT-4101 placebo, Deuterated Water - Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity | Phase 1 / Phase 2 | Terminated | Forma Therapeutics, Inc. | 14 | 2019-05-17 | 2025-10-20 |
| A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients FT-4202/Placebo - Healthy Volunteers, Sickle Cell Disease | Phase 1 | Completed | Forma Therapeutics, Inc. | 130 | 2018-12-11 | 2024-04-10 |
| A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation FT-2102, Azacitidine, Nivolumab - Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) | Phase 1 / Phase 2 | Completed | Forma Therapeutics, Inc. | 93 | 2018-11-01 | 2023-11-18 |
| Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation FT-2102 (olutasidenib), Azacitidine, Cytarabine - Acute Myeloid Leukemia, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Completed | Forma Therapeutics, Inc. | 336 | 2016-04-30 | 2026-06-29 |
| Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies FT-1101, Azacitidine - Acute Myeloid Leukemia, Acute Myelogenous Leukemia | Phase 1 | Completed | Forma Therapeutics, Inc. | 94 | 2015-09-01 | 2023-11-21 |
Anemia, Sickle Cell (5) · Myelodysplastic Syndromes (4) · Anemia (3) · Leukemia, Myeloid, Acute (3) · Anemia, Hemolytic (2) · Genetic Diseases, Inborn (2) · Hematologic Diseases (2) · Hemoglobinopathies (2) · Hemolysis (2) · Sickle Cell Trait (2) · Vaso-Occlusive Crises (2) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Glioblastoma (1)
Azacitidine (3) · olutasidenib (3) · Cisplatin (1) · Cytarabine (1) · Gemcitabine (1) · Hydroxyurea (1) · Nivolumab (1) · decitabine and cedazuridine drug combination (1)
United States (8) · Canada (5) · France (5) · United Kingdom (5) · Germany (3) · Italy (3) · Lebanon (3) · Nigeria (3) · Spain (3) · Australia (2) · Egypt (2) · India (2) · Kenya (2) · Oman (2) · South Korea (2)
Cameron Trenor, MD (1) · Emma Barrett (1) · Patrick Kelly, MD (1) · Paul Ferrell, MD (1)
PMID 35019238, PMID 36370742, PMID 36724515, PMID 37254256, PMID 38640200, PMID 39734743, PMID 39819505, PMID 40668616, PMID 41239466, PMID 41611702